To compare clinical trial results for recurrent ovarian cancer, first check whether the studies enrolled similar patients and used comparable designs. Then compare the precise definitions and follow-up for response, progression-free survival (PFS), overall survival (OS), harms, and patient-reported outcomes. A larger response rate or longer PFS in one study does not, by itself, prove that its treatment is better for a particular person—especially when the studies were not randomized against each other.
Start by checking whether the studies are comparable
“Recurrent ovarian cancer” does not describe one uniform trial population. Studies may differ in cancer histology, previous treatments, platinum sensitivity or resistance, and other eligibility requirements. Those differences can affect both the outcomes reported and how well the results apply to a patient.
As an Amazon Associate I earn from qualifying purchases.
For each study, establish:
- Who was eligible: cancer type or histology, disease setting, and important inclusion or exclusion criteria.
- What treatment participants had received: prior therapies and the study’s definition or handling of platinum-sensitive or platinum-resistant disease.
- How the study was designed: phase, number of participants, whether treatment was randomized, and what comparator—if any—was used.
NCI’s treatment overview covers recurrent or persistent ovarian, fallopian tube, and primary peritoneal cancers, while its trial records show that eligibility and regimens can vary substantially. These records are useful examples, not evidence that every listed approach suits every patient: NCI: Treatment of Ovarian Epithelial, Fallopian, and Peritoneal Cancers, EFFORT trial record, and KEYNOTE-B96 / ENGOT-ov65 trial record.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Identify what each endpoint actually measures
Endpoint names are not interchangeable. Read the protocol or results report for the exact definition, starting point, assessment schedule, analysis population, and follow-up; two studies using the same label may not measure time or response in precisely the same way.
#1 Best Overall
| Endpoint | What it measures | What to verify |
|---|---|---|
| Objective response rate (ORR) | The proportion of participants meeting the study’s definition of complete or partial tumor response. | Response criteria, assessor, assessment schedule, and which participants were counted. |
| Progression-free survival (PFS) | Time until progression or death, as defined by the study. | Time origin, definition of progression, scan schedule, follow-up, and analysis population. |
| Overall survival (OS) | Time until death from the study-defined starting point. | Time origin, follow-up, and whether the reported result is mature enough to interpret. |
| Duration of response | Time from first documented response until progression under the study’s criteria, generally among participants who responded. | Response criteria, time origin, follow-up, and number of responders included. |
| Patient-reported outcomes | Symptoms or quality of life reported directly by participants using specified instruments. | Instrument, collection timing, completion rates, and which results were reported. |
For example, an NCI trial record defines PFS from the first cycle to documented progression or death; another study may use a different time origin or scan schedule. Compare the definitions rather than assuming every PFS figure is calculated identically. NCI records may also list response and PFS separately from OS, reflecting distinct questions each endpoint answers: EFFORT trial record and avelumab and stereotactic body radiation trial record.
Check how tumor response and progression were assessed
RECIST 1.1 is used in NCI-listed ovarian cancer trials, but the trial report should say whether assessments were made by investigators or another specified method. RECIST defines tumor-response and time-to-event assessment, and the details of its application depend on the study design. Confirm the criteria, assessor, imaging schedule, and rules for determining progression before comparing results.
The RECIST 1.1 guideline authors noted that scheduled reassessment of specified disease sites is warranted when a time-to-event outcome such as PFS is the main endpoint. The guideline also cautions that an apparently promising result in an uncontrolled trial may reflect patient selection rather than the treatment’s effect. See the RECIST 1.1 guideline, published in European Journal of Cancer in 2009.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Distinguish a treatment effect from a difference between studies
A randomized study compares treatment groups within the same trial, which can support a more direct estimate of relative effect than comparing separate studies. In an uncontrolled, single-arm study, participants receive the study treatment without a randomized comparison group. Its response results describe what happened among those participants; they do not alone establish that the treatment caused the outcome or is superior to another treatment.
Rank #3
When a report gives an efficacy estimate, look for its uncertainty as well as its size: the number of participants analyzed, the estimate’s confidence interval if reported, follow-up duration, and whether the analysis was planned. A difference between two reported numbers may be difficult to interpret if the patient groups, assessment methods, or follow-up differ. Do not treat planned endpoints in a trial record as final efficacy findings.
Compare harms and the experience of treatment
Effectiveness is only part of the comparison. Review adverse events alongside the time participants were exposed to treatment, their severity, and how often treatment was stopped or changed. Check whether safety results cover all treated participants and whether the studies used comparable reporting periods or definitions.
Patient-reported symptoms and quality-of-life measures can add context that tumor scans and survival endpoints cannot provide on their own. NCI trial examples list instruments including EORTC questionnaires and NFOSI-18. Check which instrument was used, when participants completed it, how many completed the assessments, and which results were reported. Examples include the APL-2 and pembrolizumab trial record and the NRG-GY004 protocol.
Recommended Free Tools
Use trial records to check current details
- Open the NCI Ovarian Cancer Clinical Trials search and use its filters to find studies relevant to the location and situation of interest.
- Open each current record and verify recruitment status, eligibility, treatment, endpoints, and locations. These details can change, so a saved or older description may no longer reflect the current record.
- Bring the record or publication to the treating oncology team and ask how its population, prior-treatment requirements, and outcome measures compare with the patient’s situation.
This framework helps interpret evidence; it is not individualized treatment advice or a ranking of named treatments. The cited sources do not establish a universal numerical threshold that proves one treatment is better for an individual.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
